Contribution of phosphodiesterase isoenzymes and cyclic nucleotide efflux to the regulation of cyclic GMP levels in aortic smooth muscle cells

Biochemical Pharmacology

Volumn 58, Issue 10, 1999, Pages 1675-1683

  Mercapide, Javier ^a   Santiago, Esteban ^a   Alberdi, Elena ^a   Martinez Irujo, Juan J ^a  

^a UNIVERSITY OF NAVARRA   (Spain)

Author keywords

Aorta; cGMP phosphodiesterase; Cyclic GMP; Tolerance; Vascular smooth muscle cells; Zaprinast

Indexed keywords

CYCLIC GMP; ISOENZYME; PHOSPHODIESTERASE; ZAPRINAST;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; AORTA; ARTERY MUSCLE; ARTICLE; CONTROLLED STUDY; NONHUMAN; PRIORITY JOURNAL; SMOOTH MUSCLE FIBER; VASODILATATION;

ANIMALS; AORTA; ATRIAL NATRIURETIC FACTOR; BIOLOGICAL TRANSPORT; CELLS, CULTURED; CYCLIC GMP; DRUG INTERACTIONS; ISOENZYMES; MUSCLE, SMOOTH, VASCULAR; NITROPRUSSIDE; NUCLEOTIDES, CYCLIC; PHOSPHODIESTERASE INHIBITORS; PHOSPHORIC DIESTER HYDROLASES; PURINONES; SWINE; VASODILATOR AGENTS;

EID: 0032860146     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(99)00252-X     Document Type: Article

References (39)

1. Katsuki S., Arnold W.P., Murad F. Effects of sodium nitroprusside, nitroglycerin, and sodium azide on levels of cyclic nucleotides and mechanical activity of various tissues. J Cyclic Nucleotide Res. 3:1977;239-247.
2. Winquist R.J., Faison E.P., Waldman S.A., Schwartz K., Murad F., Rapoport R.M. Atrial natriuretic factor elicits an endothelium-independent relaxation and activates particulate guanylate cyclase in vascular smooth muscle. Proc Natl Acad Sci USA. 81:1984;7661-7664.
3. Waldman S.A., Murad F. Cyclic GMP synthesis and function. Pharmacol Rev. 39:1987;163-196.
4. Lincoln T.M., Komalavilas P., Cornwell T.L. Pleiotropic regulation of vascular smooth muscle tone by cyclic GMP-dependent protein kinase. Hypertension. 23:1994;1141-1147.
5. Lincoln T.M., Corbin J.D. Characterization and biological role of the cGMP-dependent protein kinase. Greengard P., Robison G.A. Advances in Cyclic Nucleotide Research. Vol. 15:1983;139-192 Raven Press, New York.
6. Palmer R.M., Ferrige A.G., Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature. 327:1987;524-526.
7. Fiscus R.R., Rapoport R.M., Waldman S.A., Murad F. Atriopeptin II elevates cyclic GMP, activates cyclic GMP-dependent protein kinase, and causes relaxation in rat thoracic aorta. Biochim Biophys Acta. 846:1985;179-184.
8. Hamet P., Pang S.C., Tremblay J. Atrial natriuretic factor-induced egression of cGMP in cultured vascular smooth muscle and endothelial cells. J Biol Chem. 264:1989;12364-12369.
9. Ahlner J., Andersson R.G.G., Torfgard K., Axelsson K.L. Organic nitrate esters Clinical use and mechanisms of action . Pharmacol Rev. 43:1991;351-423.
10. Pagani E.D., Van Aller G.S., O'Connor B., Silver P.J. Reversal of nitroglycerin tolerance in vitro by the cGMP-phosphodiesterase inhibitor zaprinast. Eur J Pharmacol. 243:1993;141-147.
11. De Garavilla L., Pagani E.D., Buchholz R.A., Dundore R., Bode D.C., Volberg M.L., Jackson K.N., Pratt P., Silver P.J. Zaprinast, but not dipyridamole, reverses hemodynamic tolerance to nitroglycerin in vivo. Eur J Pharmacol. 313:1996;89-96.
12. Beavo J.A. Cyclic nucleotide phosphodiesterases Functional implications of multiple isoforms . Physiol Rev. 75:1995;725-748.
13. Saeki T., Saito I. Isolation of cyclic nucleotide phosphodiesterase isozymes from pig aorta. Biochem Pharmacol. 46:1993;833-839.
14. Coste H., Grondin P. Characterization of a novel potent and specific inhibitor of type V phosphodiesterase. Biochem Pharmacol. 50:1995;1577-1585.
15. Miyahara M., Ito M., Itoh H., Shiraishi T., Isaka N., Konishi T., Nakano T. Isoenzymes of cyclic nucleotide phosphodiesterase in the human aorta Characterization and the effects of E4021 . Eur J Pharmacol. 284:1995;25-33.
16. Polson J.B., Strada S.J. Cyclic nucleotide phosphodiesterases and vascular smooth muscle. Annu Rev Pharmacol Toxicol. 36:1996;403-427.
17. Martin W., Furchgott R.F., Villani G.M., Jothianandan D. Phosphodiesterase inhibitors induce endothelium-dependent relaxation of rat and rabbit aorta by potentiating the effects of spontaneously released endothelium-derived relaxing factor. J Pharmacol Exp Ther. 237:1986;539-547.
18. Harris A.L., Lemp B.M., Bentley R.G., Perrone M.H., Hamel L.T., Silver P.J. Phosphodiesterase isozyme inhibition and the potentiation by zaprinast of endothelium-derived relaxing factor and guanylate cyclase stimulating agents in vascular smooth muscle. J Pharmacol Exp Ther. 249:1989;394-400.
19. Murray K.J., England P.J. Inhibitors of cyclic nucleotide phosphodiesterases as therapeutic agents. Biochem Soc Trans. 20:1992;460-464.
20. Dundore R.L., Clas D.M., Wheeler L.T., Habeeb P.G., Bode D.C., Buchholz R.A., Silver P.J., Pagani D.E. Zaprinast increases cyclic GMP levels in plasma and in aortic tissue of rats. Eur J Pharmacol. 249:1993;293-297.
21. Silver P.J., Dundore R.L., Bode D.C., De Garavilla L., Buchholz R.A., Van Aller G., Hamel L.T., Bacon E., Singh B., Lesher G.Y., Hlasta D., Pagani E.D. Cyclic GMP potentiation by WIN 58237, a novel cyclic nucleotide phosphodiesterase inhibitor. J Pharmacol Exp Ther. 271:1994;1143-1149.
22. Merkel L.A., Rivera L.M., Perrone M.H., Lappe R.W. In vitro and in vivo interactions of nitrovasodilators and zaprinast, a cGMP-selective phosphodiesterase inhibitor. Eur J Pharmacol. 216:1992;29-35.
23. Weishaar R.E., Kobylarz-Singer D.C., Keiser J., Haleen S.J., Major T.C., Rapundalo S., Peterson J.T., Panek R. Subclasses of cyclic GMP-specific phosphodiesterase and their role in regulating the effects of atrial natriuretic factor. Hypertension. 15:1990;528-540.
24. Monge A., Aldana I., Losa M.J., Font M., Castiella E., Frechilla D., Cenarruzabeitia E., Martinez-Irujo J.J., Lopez-Unzu M.J., Alberdi E., Santiago E. A novel class of cardiotonic agents Synthesis and biological evaluation of pyridazino [4,5-b] indoles with cyclic AMP phosphodiesterase inhibiting properties . J Pharm Sci. 82:1993;526-530.
25. Villahermosa M.L., Martinez-Irujo J.J., Cabodevilla F., Santiago E. Synergistic inhibition of HIV-1 reverse transcriptase by combinations of chain-terminating nucleotides. Biochemistry. 36:1997;13223-13231.
26. Kishi Y., Watanabe T., Makita T., Sakita S., Watanabe R., Ashikaga T., Numano F. Effect of nifedipine on cyclic GMP turnover in cultured coronary smooth muscle cells. J Cardiovasc Pharmacol. 26:1995;590-595.
27. Radziszewski W., Chopra M., Zembowicz A., Gryglewski R., Ignarro L.J., Chaudhuri G. Nitric oxide donors induce extrusion of cyclic GMP from isolated human blood platelets by a mechanism which may be modulated by prostaglandins. Int J Cardiol. 51:1995;211-220.
28. Houslay M.D., Milligan G. Tailoring cAMP-signalling responses through isoform multiplicity. Trends Biochem Sci. 22:1997;217-224.
29. Chini C.C., Grande J.P., Chini E.N., Dousa T.P. Compartmentalization of cAMP signaling in mesangial cells by phosphodiesterase isozymes PDE3 and PDE4. Regulation of superoxidation and mitogenesis. J Biol Chem. 272:1997;9854-9859.
30. Anand-Srivastava M.B., Trachte G.J. Atrial natriuretic factor receptors and signal transduction mechanisms. Pharmacol Rev. 45:1993;455-497.
31. Bolotina V.M., Najibi S., Palacino J.J., Pagano P.J., Cohen R.A. Nitric oxide directly activates calcium-dependent potasium channels in vascular smooth muscle. Nature. 368:1994;850-853.
32. Fehr T.F., Dickinson E.S., Goldman S.J., Slakey L.L. Cyclic AMP efflux is regulated by occupancy of the adenosine receptor in pig aortic smooth muscle cells. J Biol Chem. 265:1990;10974-10980.
33. Ahn H.S., Crim W., Romano M., Sybertz E., Pitts B. Effects of selective inhibitors on cyclic nucleotide phosphodiesterases of rabbit aorta. Biochem Pharmacol. 38:1989;3331-3339.
34. Saeki T., Adachi H., Takase Y., Yoshitake S., Souda S., Saito I. A selective type V phosphodiesterase inhibitor, E4021, dilates porcine large coronary artery. J Pharmacol Exp Ther. 272:1995;825-831.
35. Burns F., Pyne N.J. Interaction of the catalytic subunit of protein kinase A with the lung type V cyclic GMP phosphodiesterase Modulation of non-catalytic binding sites . Biochem Biophys Res Commun. 189:1992;1389-1396.
36. Wyatt TA, Naftilan AJ, Francis SH and Corbin JD, ANF elicits phosphorylation of the cGMP phosphodiesterase in vascular smooth muscle cells. Am J Physiol 274: H448-H455, 1998.
37. Turko I.V., Francis S.H., Corbin J.D. Binding of cGMP to both allosteric sites of cGMP-binding cGMP-specific phosphodiesterase (PDE5) is required for its phosphorylation. Biochem J. 329:1998;505-510.
38. 2+/calmodulin-dependent protein kinase II. J Biol Chem. 264:1989;10884-10887.
39. Silver P.J., Pagani E.D., De Garavilla L., Van Aller G.S., Volberg M.L., Pratt P.F., Buchholz R.A. Reversal of nitroglycerin tolerance by the cGMP phosphodiesterase inhibitor zaprinast. Eur J Pharmacol. 199:1991;141-142.